<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04000698</url>
  </required_header>
  <id_info>
    <org_study_id>NCPHOI-2018-08</org_study_id>
    <nct_id>NCT04000698</nct_id>
  </id_info>
  <brief_title>Personalized Targeted Preparative Regimen Before T-depleted Allogeneic HSCT in Children With Chemoresistent Acute Leukemias</brief_title>
  <official_title>A Phase I-II Pilot Clinical Trial of Safety and Efficacy of Personalized Targeted Preparative Regimen With Allogeneic TcRαβ/CD19-depleted Hematopoietic Stem Cell Transplantation and Posttransplant Donor T- Cells Infusion in Children With Chemoresistаnt Acute Leukemia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal Research Institute of Pediatric Hematology, Oncology and Immunology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal Research Institute of Pediatric Hematology, Oncology and Immunology</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficiency of personalized targeted&#xD;
      therapy in combination with high-dose chemotherapy as part of a preparative regimen before&#xD;
      T-depleted allogeneic hematopoietic stem cell transplantation in children with chemoresistant&#xD;
      acute leukemias&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The outcome of hematopoietic stem cell transplantation (HSCT) in a cohort of children with&#xD;
      chemorefractory leukemia is poor. The incidence of relapse exceeds 50% and survival varies&#xD;
      from 10 to 40%. Additional attempts at remission induction with various combinations of&#xD;
      chemotherapy are unlikely to improve the outcome and will contribute to toxicity.&#xD;
&#xD;
      The hypothesis of the study is that personalized targeted therapy combined with high-dose&#xD;
      chemotherapy may improve the outcome of allogeneic HSCT in a cohort of pediatric patients&#xD;
      with refractory leukemia.&#xD;
&#xD;
      Bcl-2, CD38, CD184 were chosen as potential targets due to frequent expression in pediatric&#xD;
      acute leukemias, availability of marketed targeted therapies venetoclax, daratumumab and&#xD;
      prelixafor, and expected non-overlapping toxicity profile of these agents and the&#xD;
      conditioning regimen.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cumulative incidence of neutrophil and platelets engraftment at day +30 after HSCT</measure>
    <time_frame>30 days after HSCT</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>30 days after HSCT</time_frame>
    <description>Proportion of patients with hematologic remission at time points</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Partial response rate</measure>
    <time_frame>30 days after HSCT</time_frame>
    <description>Proportion of patients with MRD negativity at time points</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of toxicity stage &gt; 3 according to CTCAE 5.0</measure>
    <time_frame>40 days after first drug administration</time_frame>
    <description>Proportion of patients with allergic/ anaphylaxis reaction toxicity stage &gt; 3 according to CTCAE 5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>cumulative incidence of transplant-related mortality</measure>
    <time_frame>100 days after HSCT</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of expression of target molecule on blast cells</measure>
    <time_frame>1 week before first drug administration</time_frame>
    <description>Proportion of patients with target molecule on blast cells: CD38 and/or CD 184 and/or Bcl2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cumulative incidence of acute GVHD grade II-IV</measure>
    <time_frame>120 days after HSCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cumulative incidence of chronic GvHD</measure>
    <time_frame>1 year after HSCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of immune recovery at day 30</measure>
    <time_frame>30</time_frame>
    <description>Proportion of patients with early immune recovery: T-cell, NK- cell, B-cell &gt;determined numbers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>1 year after HSCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>event-free survival</measure>
    <time_frame>1 year after HSCT</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Refractory Acute Myeloid Leukemia</condition>
  <condition>Refractory Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>intervention/treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preparative chemotherapy before allogeneic HSCT&#xD;
Fludarabin&#xD;
Cytarabine&#xD;
Venetoclax&#xD;
Daratumomab&#xD;
Vecanoid&#xD;
treosulfan&#xD;
fludarabine&#xD;
thiophosphomide&#xD;
Venetoclax&#xD;
Plerixafor&#xD;
abatacept&#xD;
tocilizumab&#xD;
rituximab&#xD;
HSCT from the haploidentical donor, ex vivo depleted of alpha/beta T lymphocytes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Preparative regimen</intervention_name>
    <description>Preparative chemotherapy before allogeneic HSCT&#xD;
Fludarabin&#xD;
Cytarabine&#xD;
Venetoclax&#xD;
Daratumomab&#xD;
Vecanoid Condition&#xD;
treosulfan&#xD;
fludarabine&#xD;
thiophosphomide&#xD;
Venetoclax&#xD;
Plerixafor GVHD prophylaxis&#xD;
abatacept&#xD;
tocilizumab&#xD;
rituximab&#xD;
HSCT from the haploidentical donor, ex vivo depleted of alpha/beta T lymphocytes</description>
    <arm_group_label>intervention/treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ability to give informed consent (for patients &gt; 14 years old). For subjects &lt; 18&#xD;
             years old their legal guardian must give informed consent&#xD;
&#xD;
          2. Disease stage&#xD;
&#xD;
               -  Acute myeloid leukemia (AML), relapsed or refractory, failure to achieve&#xD;
                  hematologic remission after at least to courses of intensive chemotherapy,&#xD;
                  including at least one course with high-dose AraC and fludarabine&#xD;
&#xD;
               -  Acute lymphoblastic leukemia (ALL), relapsed or refractory, failure to achieve&#xD;
                  hematologic remission after at least two high-dose therapy blocks&#xD;
&#xD;
          3. Patient eligible for current hematopoietic stem cell transplantation protocol&#xD;
&#xD;
          4. The BCL-2 expression must be detected on greater than 30% of tumor cells (AML and ALL)&#xD;
             by flow cytometry&#xD;
&#xD;
          5. CD38 expression must be detected on greater than 30% of tumor cells (AML and ALL) by&#xD;
             flow cytometry&#xD;
&#xD;
          6. CD184&#xD;
&#xD;
          7. Patients must have measurable or evaluable disease at the time of enrollment, which&#xD;
             may include any evidence of disease including minimal residual disease detected by&#xD;
             flow cytometry, cytogenetics, or polymerase chain reaction (PCR) analysis.&#xD;
&#xD;
          8. Patient Clinical Performance Status: Karnofsky &gt;50% or Lansky &gt;50%&#xD;
&#xD;
          9. Patient Life Expectancy &gt;12 weeks&#xD;
&#xD;
         10. Patients who agree to long-term follow up for up to 5 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &gt;25 years&#xD;
&#xD;
          -  Patients with uncontrolled infections&#xD;
&#xD;
          -  Clearance of creatinine &lt; 70 ml/min&#xD;
&#xD;
          -  Cardiac ejection fraction &lt; 40%&#xD;
&#xD;
          -  Patients who can perform pulmonary function tests will be excluded if they have a&#xD;
             diffusing capacity of the lung for carbon monoxide (DLCO) (corrected for hemoglobin)&#xD;
             of &lt; 50% predicted; patients who are unable to perform pulmonary function tests will&#xD;
             be excluded if the oxygen (O2) saturation is &lt; 92% on room air&#xD;
&#xD;
          -  Patients who have liver function test (LFTs) (including total bilirubin, aspartate&#xD;
             aminotransferase [AST] and alanine aminotransferase [ALT]) &gt;= twice the upper limit of&#xD;
             normal&#xD;
&#xD;
          -  Karnofsky/Lansky Scale &lt;70%&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Larisa Shelikhova</last_name>
    <phone>84956647078</phone>
    <email>larisa.shelikhova@fccho-moscow.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhanna Shekhovtsova</last_name>
    <phone>84956647078</phone>
    <phone_ext>7538</phone_ext>
    <email>zhanna.shekhovtsova@fccho-moscow.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology</name>
      <address>
        <city>Moscow</city>
        <zip>117997</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhanna Shekhovtsova, MD</last_name>
      <phone>4956647078</phone>
      <phone_ext>7538</phone_ext>
      <email>zhanna.shekhovtsova@fccho-moscow.ru</email>
    </contact>
    <contact_backup>
      <last_name>Eugene Pashanov, PhD</last_name>
      <phone>+79262205578</phone>
      <email>e.pashanov@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Maschan, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>June 25, 2019</study_first_submitted>
  <study_first_submitted_qc>June 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 27, 2019</study_first_posted>
  <last_update_submitted>November 19, 2020</last_update_submitted>
  <last_update_submitted_qc>November 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

